Monetising a platform technology

Ogru, Esra
October 2011
Australasian Biotechnology;Oct2011, Vol. 21 Issue 3, p30
This sector is acutely aware of the squeeze on Australian companies in raising ongoing capital. Phosphagenics is implementing a range of strategies to reduce the need to return to the market for capital. Phosphagenics' primary goal is to develop a transdermal oxycodone patch. A successfully commercialised product would tap into the $6 billion per annum market for chronic pain treatments. The oxycodone market alone is $3.2 billion per annum. Over the last few years Phosphagenics has implemented an innovative revenue creation strategy.


Related Articles

  • POSITIVE RESULTS FROM PHASE 1B OF OXYCODONE PATCH.  // Worldwide Biotech;Mar2010, Vol. 22 Issue 3, p1 

    The article reports on the positive results of the Phase 1B clinical study conducted by Phosphagenics Ltd. using its Targeted Penetration Matrix (TPMâ„¢) for the transdermal delivery of oxycodone. The trial has successfully demonstrated that daily application of a TPMâ„¢-oxycodone patch...

  • Phosphagenics working on topical opioid patch.  // Australian Life Scientist;Mar/Apr2013, Vol. 10 Issue 2, p6 

    The article informs that Phosphagenics Ltd. has included an oxycodone-based patch designed for local pain relief in its pain patch portfolio and is also planning to start clinical trials of a similar version of the patch in the third quarter.

  • R&D Update.  // PharmaWatch: CNS;Nov2007, Vol. 6 Issue 11, p10 

    The article offers news briefs related to pharmaceutical industry worldwide in 2007. Adlea is a long-acting, non-opiate analgesic drug which designed for weeks to months pain relief in single local dose during the surgical procedure. Australian company Phosphagenics has received approval to...

  • Transdermal Buprenorphine. Likar, Rudolf // Drugs;2003, Vol. 63 Issue 19, p2011 

    Reports on the use of a transdermal therapeutic system containing buprenorphine to manage pain. Avoidance of gastrointestinal passage and first-pass metabolism; Continuous slow release of buprenorphine at a defined rate from its polymer matrix into the blood; Efficacy and safety of transdermal...

  • Use of Transdermal Fentanyl in Patients with Continuous Non-Malignant Pain: A Case Report Series. Libretto, S.E. // Clinical Drug Investigation;2002, Vol. 22 Issue 7, p473 

    Objective: The aim of this case report series is to detail the use in a clinical setting of transdermal fentanyl patches for the treatment of patients with continuous non-malignant pain. Case reports: These cases, collected in Ireland, describe patients with back pain, leg pain, arthritic pain...

  • Transdermal Fentanyl for Postoperative Pain Management. Caplan, Robert A.; Ready, L. Brian; Oden, Rollin V.; Matsen III, Frederick A.; Nessly, Michael L.; Olsson, Gayle L. // JAMA: Journal of the American Medical Association;2/17/89, Vol. 261 Issue 7, p1036 

    Evaluates the safety and efficacy of transdermal fentanyl citrate for post-operative pain management in patients undergoing shoulder injury. Effects on the incidence of vomiting and respiratory rate; Percentage of patients exhibiting episodes of narcotic-related side effects during application...

  • When Your Pain Patient Has Trouble Falling Asleep. Scholz, Mary J. // RN;May2002, Vol. 65 Issue 5, p98 

    Presents a question and answer advisory on pain management. Effects of oxycodone on the sleeping process of patients; Use of a sedative-hypnotic medicine to help patients with chronic back pain to sleep; Risk associated with zolpidem.

  • Comparison of oxycodone and sufentanil for patient-controlled intravenous analgesia after laparoscopic radical gastrectomy: A randomized double-blind clinical trial. Na Wang; Xuesong Song; Honglan Zhou; Jinguo Wang // Anesthesia: Essays & Researches;Sep-Dec2016, Vol. 10 Issue 3, p557 

    Background: Sufentanil is widely used for patient-controlled intravenous analgesia (PCIA). Oxycodone has a powerful analgesic effect and mild side effects. We conducted this study to compare the efficacy of oxycodone and sufentanil for PCIA on postoperative pain after laparoscopic radical...

  • Home based application of transdermal cryoanalgesia as interventional pain management among Nigerian physiotherapists. Teslim, Onigbinde Ayodele; Talabi, A. E.; Olaoye, O.; Oniyangi, S.; Olaitan, O. L.; Odeyemi, E. // Sports Medicine Journal / Medicina Sportivâ;2012, Vol. 8 Issue 1, p1775 

    Aim and scope: The primary purpose of this study was to sample the opinion of physiotherapists on the prescription of cryoanalgesia for patients' home based use in Nigeria. Material and methods: A total of 152 physiotherapists (PTs) were selected from hospitals in south-west Nigeria. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics